HHS & Healthcare Contracts Intelligence — June 17, 2026

Leidos Biomedical Research won a $126.4M cost-plus-fixed-fee delivery order from NIH NCI for R&D facility space management, with $74.2M already outlayed and ~$52.2M remaining. The full-and-open competition and cost-plus structure indicate stable, low-margin revenue through August 2024.

NIH NCI budget appropriations for FY2024 are uncertain, potentially impacting the remaining $52.2M obligated funding or follow-on contract awards for Leidos.

Leidos' reliance on a single GOCO facility management contract for ~$25.3M annual revenue in its health segment creates concentration risk, especially with no options for extension beyond 2024.

Leidos could leverage its performance on this NIH NCI GOCO contract to bid on similar R&D facility management awards at other NIH institutes or federal life sciences agencies, expanding its civilian health services footprint.

This award underscores the durability of NIH-funded R&D facility operations, which provide predictable, low-risk revenue for contractors like Leidos despite cost-plus margin constraints.

{"entity"=>"Leidos Holdings, Inc.", "reason"=>"The $126.4M NIH NCI contract ends August 2024, with no options. Leidos must secure follow-on work to avoid a revenue gap in its health segment.", "trigger"=>"NIH NCI re-compete announcement or extension for GOCO facility management at Frederick"}

{"entity"=>"NIH National Cancer Institute", "reason"=>"NCI budget appropriations for FY2024 will determine the availability of funds for the remaining $52.2M obligation and any follow-on contracts.", "trigger"=>"FY2024 NIH budget passage or continuing resolution"}